SB 332 revises Oklahoma’s medical marijuana business licensing law by setting a new fee structure for the Oklahoma Medical Marijuana Authority to use when issuing and renewing licenses. The bill keeps the existing license categories—grower, processor, dispensary, transporter, and testing laboratory—but replaces or clarifies several fee amounts and formulas, especially for commercial growers and processors. It establishes tiered annual fees based on canopy size for indoor/greenhouse/light deprivation grow operations, acreage for outdoor grow operations, biomass or concentrate volume for processors, a transporter fee of $2,500, a testing laboratory fee of $20,000, and a dispensary fee tied to 10% of the prior year’s state sales and excise tax collections, subject to a floor and cap. The bill also preserves and restates application procedures, background-check requirements, residency standards, ownership disclosure rules, and renewal deadlines.
The bill would amend 63 O.S. 2021, Section 427.14, affecting the licensing and regulatory framework for medical marijuana businesses in Oklahoma. It would require separate licenses for indoor and outdoor grow operations at the same location, define key terms such as canopy, greenhouse, and light deprivation, and authorize the Authority to invoice applicants for additional fees before approval. It also reinforces compliance obligations for applicants and licensees, including fingerprint-based background checks, proof of Oklahoma residency, tax compliance, zoning compliance, employee credentialing, and late-renewal penalties. The bill further clarifies that expired licenses cannot be renewed after 60 days and that continued marijuana business activity after expiration can trigger felony exposure under existing controlled substances law.
Overall, the sentiment reflected in the available record is neutral to supportive in the sense that the bill appears to be a technical and fiscal update to the medical marijuana licensing system rather than a major policy overhaul. There are no committee transcripts or recorded votes in the provided materials, so there is no direct evidence of debate, opposition, or amendments from floor or committee discussion. The bill’s movement to the Business and Insurance Committee and then Appropriations suggests it was treated as a measure with both regulatory and revenue implications.
The main points of contention likely center on the fee increases and the tiered structure, especially for larger growers and processors, as well as the dispensary fee formula and the higher cost of compliance for applicants and renewals. The bill also maintains strict eligibility rules, including age, residency, criminal history, and tax-payment requirements, which could be viewed as barriers by industry participants. Another possible area of concern is the continued authority of the OMMA and law enforcement agencies to investigate ownership and enforce licensing standards, which may be seen as necessary oversight by supporters but burdensome by operators.
SB 332 would amend Oklahoma’s medical marijuana business licensing statute, 63 O.S. 2021, Section 427.14, by replacing and clarifying license fee schedules and reinforcing application, renewal, and compliance requirements for medical marijuana businesses. It would directly affect growers, processors, dispensaries, transporters, and testing laboratories by imposing tiered annual fees, updating dispensary fee calculations, setting late-renewal penalties, and preserving strict licensing conditions tied to residency, background checks, tax compliance, and zoning. The bill also authorizes the Oklahoma Medical Marijuana Authority to implement the fee system through rulemaking and to continue using detailed application and review procedures for licensure.
The available record suggests a generally neutral-to-supportive sentiment, with the bill appearing to be a regulatory and fee-structure update rather than a controversial policy shift. No committee transcript or vote data is provided, so there is no documented public debate in the materials. Its referral to Business and Insurance and then Appropriations indicates it was treated as a measure with administrative and fiscal significance.
The most likely areas of contention are the new or revised licensing fees, especially the tiered grower and processor charges and the dispensary fee tied to tax collections, which could increase costs for operators. Industry participants may also object to the bill’s strict residency, criminal-history, tax-compliance, and renewal rules, as well as the late-renewal penalties and the inability to renew licenses more than 60 days after expiration. Supporters would likely view these provisions as necessary to strengthen oversight, ensure compliance, and standardize licensing across the medical marijuana market.